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Clinical Capsule Report
False-Positive Cholesteatomas on Non-Echoplanar
Diffusion-Weighted Magnetic Resonance Imaging
Ethan G. Muhonen, Hossein Mahboubi, Omid Moshtaghi, yRonald Sahyouni, Yaser Ghavami,
Marlon Maducdoc, Harrison W. Lin, and yHamid R. Djalilian
Division of Neurotology and Skull Base Surgery, Department of Otolaryngology–Head and Neck Surgery; and
yDepartment of Biomedical Engineering, University of California, Irvine, California
Objectives: To investigate false-positive findings on non-
echoplanar (non-EPI) diffusion-weighted magnetic resonance
imaging (DWI) in patients under surveillance post-cholestea-
toma surgery.
Study Design, Setting, Subjects, and Methods: A retro-
spective review was performed on patients diagnosed with
cholesteatoma who underwent surgical resection and were
then followed by serial non-EPI DWI using half-Fourier
acquisition single-shot turbo spin echo (HASTE) sequence.
All patients had at least two annual follow-up imaging
studies.
Results: False-positive findings were identified in four
patients. The size of the suspected lesions was 4 to 12 mm.
Otoendoscopy was used during all primary cases and Argon
laser was used in one case. In all cases, the entire
cholesteatoma was removed, and no residual disease was
detected at the end of the procedures. One patient underwent
revision surgery but only cartilage graft was found in the
area of concern. All patients had stable or resolved hyperin-
tense areas in the subsequent HASTE sequences.
Conclusion: False positive findings can occur with non-EPI
DWI MRI and patients need to be counseled accordingly
before revision surgery. Decreasing intensity and dimension
of a suspected lesion and a positive finding in an area other
than the location of the initial cholesteatoma may favor a
false positive. If a false positive finding is suspected when
the surgeon is confident of complete resection of the
cholesteatoma, an MRI can be repeated in 6 to 12 months to
assess changes in the dimension and intensity of the area of
concern. Cartilage grafts may cause restricted diffusion on
DWI sequences. Key Words: Cholesteatoma—Diffusion-
weighted magnetic resonance imaging—Half-Fourier
acquisition single-shot turbo spin echo—Magnetic resonance
imaging—Non-echoplanar diffusion weighted imaging—
Recidivism—Surveillance.
Otol Neurotol 41:xxx–xxx, 2020.
Cholesteatoma recidivism and its surveillance remain
a challenge in otologic surgery (1). The recidivism rate,
encompassing residual, and recurrent cases, has been
reported at 5 to 17% after canal-wall-down (CWD)
surgeries and 9 to 70% after intact-canal-wall (ICW)
surgeries (2). Historically, a staged, second-look surgery
in 6 to 12 months after the initial surgery has been the
gold standard to address potential residual or recurrent
disease (3). These second-look surgeries are associated
with higher costs and increased number of postoperative
visits compared with single-stage surgeries, and no cho-
lesteatoma is found in approximately 52.0 to 67% of
patients (3–5).
Diffusion-weighted magnetic resonance imaging
(DWI) has gained popularity in the past decade as the
preferred imaging study for cholesteatoma surveillance
(6–9). The non-echo-planar (non-EPI) DWI has been
found to be superior to echo-planar DWI and other
magnetic resonance imaging (MRI) variants as it enables
differentiation between cholesteatoma and inflammation,
has thinner slices, and generates less artifact (10). As
such, the non-EPI technique can potentially decrease
unnecessary second-look surgeries (11). A 2011 system-
atic review estimated the pooled sensitivity and specific-
ity of non-EPI DWI in finding cholesteatomas to be 91.4
and 95.8%, respectively (10).
With increasing utilization for post-surgical choles-
teatoma surveillance, false-positive non-EPI DWI
images can drive unnecessary revision surgeries. While
sensitivity, specificity, and positive predictive value have
been well-described in the literature, false-positive non-
EPI DWIs have not. Therefore, in the current study we
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investigated false-positive cases in our patient population
under surveillance with non-EPI DWI after cholestea-
toma surgery to describe their characteristics and man-
agement outcomes.
METHODS
This study was approved by the University of California
Irvine Institutional Review Board. A retrospective chart
review was performed on patients with a history of surgery
for removal of cholesteatoma all performed by the senior
author during 2007 to 2017. In our practice, non-EPI DWI
is used for cholesteatoma surveillance in most patients on an
annual basis for 3 years. A final MRI is obtained at the 5-year
postoperative time point. The patients are also clinically
followed on an annual or semi-annual basis for a thorough
otologic examination. We perform a canal wall down mastoid-
ectomy on most cholesteatoma patients, and obliterate the
mastoid cavity with cartilage grafts and bone pate.
The study inclusion criteria were cholesteatoma surveillance
with serial non-EPI DWIs and at least two annual follow-up
imaging studies. False positive cases were defined as patient
with areas of hyperintensity with subsequent decrease or reso-
lution in follow-up imaging. Additionally, patients with posi-
tive MRIs who underwent second look and had no evidence of
cholesteatoma were included in the study. Data for demo-
graphics, side and type of surgery, location of initial choles-
teatoma, and findings on DWI were collected and analyzed.
MRI examinations were performed on one of three machines
using a standard head coil and included coronal non-EPI DWI
(HASTE, half Fourier acquisition single-shot turbo spin echo)
without contrast injection. This includes a 1.5-T MRI scanner
(Avanto, Siemens, Erlangen, Germany) with the following
coronal DWI parameters: repetition time (TR)/echo time
(TE), 2000/109 ms and 3 mm slice thickness with 3.3 mm
spacing; field of view (FOV) 220 220 mm; b-value 0 and
1000; a 3-T MRI scanner (TrioTim, Siemans, Erlangen,
Germany) with the following coronal DWI parameters: TR/
TE 2500/92 ms and 3 mm slice thickness with 3 mm spacing;
FOV 220 220 mm; b-value 0 and 800; or a 3-T MRI scanner
(MAGNETOM Vida, Siemens, Erlangen, Germany) with the
following coronal DWI parameters: TR/TE 4500/68 ms and
3 mm slice thickness with 3.9 mm spacing; FOV 204 204 mm;
b-value 0 and 800.
RESULTS
Of 369 patients followed by serial MRIs for cholestea-
toma surveillance, four patients were identified who met
the inclusion criteria. Table 1 summarizes their demo-
graphics and characteristics. The age at the time of surgery
ranged from 5 to 57 years. All underwent CWD surgeries
with bone and cartilage grafts for obliteration of the
mastoid and scutum (Table 1). One patient had a middle
cranial fossa approach for a congenital epidermoid, which
involved the tegmen tympani and the geniculate ganglion
and labyrinthine portion of the facial nerve. Intraoperative
otoendoscopy was used in conjunction with microscopy in
all primary cases to assist in detection of any potential
residual disease that could not be directly visualized via the
operative microscope. Argon laser was used in one case to
assist in vaporizing microscopic foci of residual disease
(case No. 4). In all cases, the entire cholesteatoma was
removed, and no residual disease was visualized at the end
of the procedure.
Review of the postoperative images revealed findings
concerning for recurrent cholesteatoma in all patients as
summarized in Table 1. The size of the areas of restricted
diffusion ranged from 4 to 8 mm. The first patient in our
series underwent a second look surgery with no choles-
teatoma found intraoperatively, and only cartilage grafts
present in the area corresponding to the noted hyper-
intensity on the HASTE sequence. Patients followed with
clinical examination and imaging all showed stable or
resolved areas of previous hyperintensity (Fig. 1).
DISCUSSION
Our study highlights four cases of false positive MRI
DWI HASTE sequences. One patient underwent surgery
which showed no evidence of cholesteatoma. The other
TABLE 1. Demographics and patient characteristics
No. Age Sex Ear
Cholesteatoma
Location
Surgery
Type Laser Otoendoscopy DWI Findings
Revision
Surgery
Subsequent
Imaging
1 50 M R Mastoid and EAC CWD
CG
BG
 þ 8 mm focus in
antrum by tegmen
 Stable
2 48 F R Epitympanum and
mastoid antrum
down to horizontal
canal
CWD
CG
BG
 þ 6 mm focus in
mastoid antrum
4 mm in Prussak’s
space
 Resolved
3 57 M R Epitympanum and
mastoid involving
tegmen mastoideum
CWD
CG
BG
 þ 10 mm focus in
mastoid antrum
þ Resolved
4 5 F R Tegmen tympani and
labyrinthine portion
of facial nerve
Middle
fossa
approach
BG
þ þ 5 mm focus in
tegmen tympani
and floor of
middle fossa
 Resolved
BG indicates bone graft; CG, cartilage graft; CWD, canal wall down; DWI, diffusion-weighted imaging; EAC, external auditory canal;
F, female; L, left; M, male; R, right.
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FIG. 1. Non-echoplanar DWI imageswith false positive findings. A,A 10mm focuswasnoted at12months post-op (leftpanel). A revisionsurgery
was performed but no cholesteatoma was identified. The focus resolved in subsequent imaging studies and no concerning foci were noted up to
52monthspost-op (rightpanel).B,A5mmfocuswasnoted in tegmen tympaniand floorofmiddle fossaat65monthspost-op (leftpanel) incaseNo.
4. This focus later resolved and no recidivism was noted at 84 months post-op (right panel). C, A 12mm focus was noted in mastoid at 12 months
post-op (left panel), which resolved at 18 months (right panel). DWI indicates diffusion-weighted magnetic resonance imaging.
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patients had subsequent imaging that revealed stable or
completely resolved areas of hyperintensity.
Size and location of a cholesteatoma, as well as
surgical approach and surgeon experience can influence
recidivism (5,9,12). Certain locations including the pos-
terior crus of the stapes, sinus tympani, and lateral
epitympanum are difficult to visualize intraoperatively,
especially in ICW procedures (13). As such, surgeons
may perform a CWD procedure, or augment procedures
with otoendoscopy and lasers to decrease the risk of
residual disease (14,15).
Various imaging modalities have been evaluated for
postoperative cholesteatoma recidivism surveillance.
The outcomes for computed tomography (CT) scanning
are poor, with reported sensitivity and specificity of 43.8
and 51.3% in detecting residual or recurrent cholestea-
toma (16). T2-weighted and post-gadolinium T1-
weighted MRIs have also been found to have a low
sensitivity and specificity of 57.1 and 63.6%, respec-
tively (17). DWI is an MRI technique based on detecting
molecular diffusion, where tissues in which water mol-
ecules have restricted movements, such as keratin debris,
return with high signal intensity (18). Of several
described methods of performing DWI, non-EPI sequen-
ces can detect cholesteatomas as small as 3 mm, and have
been found to be superior to echo-planar sequences with
respect to sensitivity (91.4% versus 70.6%) and specific-
ity (95.8% versus 87.3%) (10,19). Echoplanar DWI
sequences are more prone to artifact at the junction
between the tissues with different magnetic susceptibili-
ties, such as in the temporal bone where air-bone and
bone-brain interfaces exist (9,10). Non-EPI DWI sequen-
ces (such as HASTE) have the advantage of reducing the
artifact at the bone-brain junction and better demonstrat-
ing residual cholesteatoma, especially when superiorly
located (10). Apparent diffusion coefficient (ADC) map-
ping of decreased signal intensity ratios can be of benefit
in avoiding confounding by T2 shine-through in non-EPI
DWI cholesteatoma surveillance (20). However, this
process is technically challenging for small lesions and
not routinely performed at our institution. This is a
limitation of our study, and the incorporation of ADC
mapping to interrogate hyperintense non-EPI DWI sig-
nals in cholesteatoma surveillance warrants further
investigation.
Imaging surveillance is most appropriate in cases
where the disease is not extensive, and the entire choles-
teatoma matrix and its keratin debris have been reliably
resected (21). False-positive cases of cholesteatoma are
rare in non-EPI DWI, but can occur (22,23). In one study,
27 patients underwent second-look surgery after detec-
tion of increased signal intensity on non-EPI DWI and
two were found to be false-positives (24). In other studies
of non-EPI DWIs, false-positives have been reported as a
result of encephalocele (25), abscess cavity (26), bone
pate (27), and wax/keratin debris (28,29).
All four of the patients in our series had cartilage or
bone grafts in the area that showed restricted diffusion. In
the patient who underwent surgery, only cartilage graft
was present at the area of concern. This suggests that
cartilage grafts may mimic cholesteatoma appearance on
non-EPI DWI series in the short term. Therefore, we
think our work is the first to add cartilage grafts into the
differential for a false-positive. If a false-positive finding
is suspected and the surgeon is confident of complete
initial resection, a non-EPI DWI study should be repeated
in 6 to 12 months. Decreasing dimensions and intensity
of a suspected lesion and a positive finding in an area
other than the location of the initial cholesteatoma may
favor a false-positive. If the lesion persists, has increasing
dimension/intensity, or the patient develops additional
findings consistent with residual disease, a revision
surgery must be considered.
CONCLUSION
False-positive findings can occur in non-EPI DWI in
patients under imaging surveillance after cholesteatoma
surgery. Decreasing dimensions of a suspected lesion and
a positive finding in an area other than the location of the
initial cholesteatoma may favor a false positive. Cartilage
grafts may cause diffusion restriction and result in false-
positive findings. If a false-positive finding is suspected
when the surgeon is confident of complete resection of
the cholesteatoma, a non-EPI DWI MRI can be repeated
in 6 months to 12 months to assess changes in the
dimensions and intensity of the area of concern.
REFERENCES
1. Kerckhoffs KG, Kommer MB, van Strien TH, et al. The disease
recurrence rate after the canal wall up or canal wall down technique
in adults. Laryngoscope 2016;126:980–7.
2. Tomlin J, Chang D, McCutcheon B, et al. Surgical technique and
recurrence in cholesteatoma: a meta-analysis. Audiol Neurootol
2013;18:135–42.
3. Keeler JA, Kaylie DM. Cholesteatoma: Is a second stage necessary?
Laryngoscope 2016;126:1499–500.
4. Crowson MG, Ramprasad VH, Chapurin N, et al. Cost analysis and
outcomes of a second-look tympanoplasty-mastoidectomy strategy
for cholesteatoma. Laryngoscope 2016;126:2574–9.
5. McRackan TR, Abdellatif WM, Wanna GB, et al. Evaluation of
second look procedures for pediatric cholesteatomas. Otolaryngol
Head Neck Surg 2011;145:154–60.
6. Jeunen G, Desloovere C, Hermans R, et al. The value of magnetic
resonance imaging in the diagnosis of residual or recurrent acquired
cholesteatoma after canal wall-up tympanoplasty. Otol Neurotol
2008;29:16–8.
7. Venail F, Bonafe A, Poirrier V, et al. Comparison of echo-planar
diffusion-weighted imaging and delayed postcontrast T1-weighted
MR imaging for the detection of residual cholesteatoma. AJNR Am J
Neuroradiol 2008;29:1363–8.
8. Huins CT, Singh A, Lingam RK, et al. Detecting cholesteatoma
with non-echo planar (HASTE) diffusion-weighted magnetic reso-
nance imaging. Otolaryngol Head Neck Surg 2010;143:141–6.
9. Corrales CE, Blevins NH. Imaging for evaluation of cholesteatoma:
current concepts and future directions. Curr Opin Otolaryngol Head
Neck Surg 2013;21:461–7.
10. Jindal M, Riskalla A, Jiang D, et al. A systematic review of
diffusion-weighted magnetic resonance imaging in the assessment
of postoperative cholesteatoma. Otol Neurotol 2011;32:1243–9.
11. Aarts MC, Rovers MM, van der Veen EL, et al. The diagnostic
value of diffusion-weighted magnetic resonance imaging in detect-
ing a residual cholesteatoma. Otolaryngol Head Neck Surg
2010;143:12–6.
4 E. G. MUHONEN ET AL.
Otology & Neurotology, Vol. 41, No. xx, 2020
Copyright © 2020 Otology & Neurotology, Inc. Unauthorized reproduction of this article is prohibited.
CE: D.C.; MAO/ON-19-633; Total nos of Pages: 5;
ON-19-633
12. Neudert M, Lailach S, Lasurashvili N, et al. Cholesteatoma recidi-
vism: comparison of three different surgical techniques. Otol
Neurotol 2014;35:1801–8.
13. Hulka GF, McElveen JT Jr. A randomized, blinded study of canal
wall up versus canal wall down mastoidectomy determining the
differences in viewing middle ear anatomy and pathology. Am J
Otol 1998;19:574–8.
14. Rehl RM, Oliaei S, Ziai K, et al. Tympanomastoidectomy with
otoendoscopy. Ear Nose Throat J 2012;91:527–32.
15. Kuo CL, Liao WH, Shiao AS. A review of current progress in
acquired cholesteatoma management. Eur Arch Otorhinolaryngol
2015;272:3601–9.
16. Blaney SP, Tierney P, Oyarazabal M, et al. CT scanning in ‘‘second
look’’ combined approach tympanoplasty. Rev Laryngol Otol Rhi-
nol (Bord) 2000;121:79–81.
17. Vanden Abeele D, Coen E, Parizel PM, et al. Can MRI replace a
second look operation in cholesteatoma surgery? Acta Otolaryngol
1999;119:555–61.
18. Lingam RK, Bassett P. A meta-analysis on the diagnostic perfor-
mance of non-echoplanar diffusion-weighted imaging in detecting
middle ear cholesteatoma: 10 years on. Otol Neurotol 2017;
38:521–8.
19. Li PM, Linos E, Gurgel RK, et al. Evaluating the utility of non-echo-
planar diffusion-weighted imaging in the preoperative evaluation of
cholesteatoma: a meta-analysis. Laryngoscope 2013;123:1247–50.
20. Suzuki H, Sone M, Yoshida T, et al. Numerical assessment of
cholesteatoma by signal intensity on Non-EP-DWI and ADC maps.
Otol Neurotol 2014;35:1007–101.
21. Lin JW, Oghalai JS. Can radiologic imaging replace second-look
procedures for cholesteatoma? Laryngoscope 2011;121:4–5.
22. Velthuis S, van Everdingen KJ, Quak JJ, et al. The value of non-
echo planar, diffusion-weighted magnetic resonance imaging for
the detection of residual or recurrent middle-ear cholesteatoma. J
Laryngol Otol 2014;128:599–603.
23. Horn RJ, Gratama JWC, van der Zaag-Loonen HJ, et al. Negative
predictive value of non-echo-planar diffusion weighted MR imag-
ing for the detaction of residual cholesteatoma dona at 9 months
after primary surgery is not high enough to omit second look
surgery. Otol Neurotol 2019;40:911–9.
24. Dremmen MH, Hofman PA, Hof JR, et al. The diagnostic accuracy
of non-echo-planar diffusion-weighted imaging in the detection of
residual and/or recurrent cholesteatoma of the temporal bone. AJNR
Am J Neuroradiol 2012;33:439–44.
25. Dhepnorrarat RC, Wood B, Rajan GP. Postoperative non-echo-
planar diffusion-weighted magnetic resonance imaging changes
after cholesteatoma surgery: implications for cholesteatoma screen-
ing. Otol Neurotol 2009;30:54–8.
26. Profant M, Slavikova K, Kabatova Z, et al. Predictive validity of
MRI in detecting and following cholesteatoma. Eur Arch Otorhi-
nolaryngol 2012;269:757–65.
27. Dubrulle F, Souillard R, Chechin D, et al. Diffusion-weighted MR
imaging sequence in the detection of postoperative recurrent cho-
lesteatoma. Radiology 2006;238:604–10.
28. Patel B, Hall A, Lingam R, et al. Using non-echoplanar diffusion
weighted MRI in detecting cholesteatoma following canal down
mastoidectomy - our experience with 20 patient episodes. J Int Adv
Otol 2018;14:263–6.
29. Lingam RK, Khatri P, Hughes J, et al. Apparent diffusion coefficients
for detection of postoperative middle ear cholesteatoma on non-
echoplana diffusion-weighted images. Radiology 2013;269:504–10.
FALSE-POSITIVE CHOLESTEATOMAS ON DWI 5
Otology & Neurotology, Vol. 41, No. xx, 2020
